Cargando…

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen

INTRODUCTION: There is paucity of data on sofosubvir (SOF)−based therapy in patients on maintenance hemodialysis (MHD). The objective of this report is to describe our experience using SOF-based direct antiviral agent (DAA) therapy in MHD patients in India. METHODS: All patients on MHD and treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agarwal, Sanjay Kumar, Bagchi, Soumita, Yadav, Raj Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733818/ https://www.ncbi.nlm.nih.gov/pubmed/29270489 http://dx.doi.org/10.1016/j.ekir.2017.04.003

Ejemplares similares

Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis
por: Shahid, Salman, et al.
Publicado: (2023)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction
por: Cox‐North, Paula, et al.
Publicado: (2017)

Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

The International IgA Nephropathy Network Prediction Tool Underestimates Disease Progression in Indian Patients
por: Bagchi, Soumita, et al.
Publicado: (2022)

Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
por: Esteban, Rafael, et al.
Publicado: (2022)

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens
por: Chen, Jianhong, et al.
Publicado: (2017)

Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation
por: Reddy, Suresh, et al.
Publicado: (2018)

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials
por: Younossi, Zobair, et al.
Publicado: (2017)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
por: Mir, Fazia, et al.
Publicado: (2017)

Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report
por: Tchoupe, Marius Djoumbissie, et al.
Publicado: (2021)

Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study
por: Bagchi, Soumita, et al.
Publicado: (2021)

Utility and patient acceptance of telemedicine in nephrology
por: George, Kristin, et al.
Publicado: (2022)

Clinical Profile of Nonproteinuric Kidney Disease in Type 2 Diabetic Patients in India
por: Sangha, Sukhwinder, et al.
Publicado: (2023)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China
por: Hu, Chengguang, et al.
Publicado: (2018)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

Profile of Indian Patients With Membranous Nephropathy
por: Subramanian, Priyadarsani, et al.
Publicado: (2020)

Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States
por: Jayasekera, Channa R., et al.
Publicado: (2017)

Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand
por: Sirinawasatien, Apichet, et al.
Publicado: (2020)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir
por: Ismail, Elshahat Ibrahem, et al.
Publicado: (2018)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Hydroxychloroquine Reduces Proteinuria in Indian Patients With IgA Nephropathy
por: Bagchi, Soumita, et al.
Publicado: (2022)

Moxifloxacin-associated Neutropenia in a Patient Planned for Renal Transplantation
por: Subbiah, Arunkumar, et al.
Publicado: (2019)

Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India
por: Bloom, David E., et al.
Publicado: (2021)

The Efficacy and Safety of Sofosbuvir/Ledipasvir Therapy in Patients on Long-term Hemodialysis with Hepatitis C Virus Infection
por: Cavoli, G. Li, et al.
Publicado: (2018)

Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation
por: Khemichian, Saro, et al.
Publicado: (2015)

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis
por: Zhang, Wenyan, et al.
Publicado: (2023)

To Study the Impact of Donor Nephrectomy on Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring and Renal Function
por: Yadav, Raj K., et al.
Publicado: (2019)

Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population
por: Stewart, Rachel A., et al.
Publicado: (2018)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
por: Sperl, Jan, et al.
Publicado: (2017)

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa
por: Boyer, Sylvie, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
por: Zhou, Hui Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kfc4uaelolljti31b9soju9e8l